Author: Ravi Shankar

Recognized leader in RNAi drug discovery with track record of advancing novel delivery platforms and therapeutics to drive Company’s integrin-mediated delivery platform

SOUTH SAN FRANCISCO, Calif., Oct. 20, 2026 (GLOBE NEWSWIRE) — Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical-stage biotechnology company focused on the discovery and development of integrin-based therapeutics, today announced the appointment of Craig Blanchette, Ph.D., as Senior Vice President, Research (siRNA). Dr. Blanchette is an accomplished biopharmaceutical research and development executive with more than two decades of drug discovery and development expertise, including a deep proficiency in RNAi and oligonucleotide chemistry, as well as delivery.

“I am excited to welcome Craig to the team and to see his contributions in realizing the potential of our proprietary integrin-mediated delivery platform,” said Bernard Coulie, M.D., Ph.D., President and Chief Executive Officer of Pliant. “Craig’s experience in advancing novel delivery platforms and leading siRNA programs from discovery to clinical development will significantly augment Pliant’s deep integrin chemistry and biology expertise.”

Dr. Blanchette joins Pliant from Switch Therapeutics, most recently serving as Chief Scientific Officer. At Switch, Dr. Blanchette built a cross-functional RNAi discovery organization from inception, converted a proprietary platform into a three-program pipeline and advanced two programs through development-candidate nomination into IND-enabling studies. Prior to Switch, Dr. Blanchette held roles of increasing responsibility at Genentech, most recently serving as Head of Protein Chemistry where he led the oligonucleotide delivery strategy and drove strategic portfolio decisions across multiple therapeutic modalities. Prior to Genentech, Dr. Blanchette served as a staff scientist in the Biological Sciences Department at Lawrence Livermore National Laboratories where he led a team to build multiple vaccine programs using novel nanoparticle technology. Dr. Blanchette received his B.S. in Biology and Physics from Vassar College and his Ph.D. in Biophysics from the University of California, Davis.

“I am thrilled to join Plaint at such a pivotal moment,” said Dr Blanchette. “The integrin-targeting small molecule discovery platform Pliant has built over the past decade holds immense promise for delivering RNAi to high-value tissues and realizing its full potential for patients with diseases of high unmet need.”

About Pliant Therapeutics, Inc.

Pliant Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery and development of integrin-based therapeutics. Pliant’s lead program is PLN-101095, a small molecule, dual-selective inhibitor of αvß8 and αvß1 integrins, that is being developed for the treatment of ICI-refractory advanced or metastatic solid tumors. PLN-101095 is being investigated in FORTIFY, a Phase 1b indication expansion trial enrolling patients with NSCLC, tumors with high tumor mutational burden or clear cell renal cell carcinoma. Pliant’s preclinical research is focused on tissue-specific delivery and internalization of drug payloads utilizing integrin receptor-binding molecules with programs focused on delivering siRNAs to skeletal muscle cells, adipocytes, and renal cells. For additional information, please visit: www.PliantRx.com. Follow Pliant on social media at X, LinkedIn and Facebook.

Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

In connection with the commencement of Dr. Blanchette’s employment with the Company, on October 19, 2026 (the “Grant Date”), the Company granted him non-statutory stock options to purchase an aggregate of 300,000 shares of Company common stock (the “Inducement Grant”). The Inducement Grant was granted under the Company’s 2022 Inducement Plan (the “Plan”) and is subject to the terms and conditions of the Plan.  The Inducement Grant was granted as an inducement material to Dr. Blanchette entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4). The Inducement Grant has an exercise price per share that is equal to the closing price of the Company’s common stock on the Grant Date. The Inducement Grant will vest over a four-year period, with 25% of the shares vesting on the one-year anniversary of Dr. Blanchette’s start date, and thereafter the remainder of the shares vest in 36 equal monthly installments, subject to Dr. Blanchette’s continued employment with the Company through the applicable vesting dates.

Investor and Media Contact:
Christopher Keenan
Vice President, Investor Relations and Corporate Communications
Pliant Therapeutics, Inc.
ir@pliantrx.com

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/0dfc4eb8-78c5-4447-ab44-366fa5b8e34b

ACR-7280 demonstrated complete tumor regression in aggressive AML xenograft models

Prioritized among multiple AP3-discovered, highly selective CDK11 inhibitor candidates based on potent single agent activity and strong synergy with BCL-2 and menin inhibitors

IND-enabling studies ongoing with IND submission on track for first half of 2027

WATERTOWN, Mass., Oct. 20, 2026 (GLOBE NEWSWIRE) — Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical-stage biotechnology company discovering and developing precision medicines utilizing its proprietary Generative Phosphoproteomics AP3 (Acrivon Predictive Precision Proteomics) platform deployed for rational drug design and predictive clinical development, today announced the advancement of ACR-7280, a potential first-in-class, oral CDK11 inhibitor, as its next development candidate generated from its AI-enabled AP3 innovation platform. Investigational New Drug (IND)-enabling studies are underway, and the company remains on track to submit an IND to the U.S. Food and Drug Administration (FDA) in the first half of 2027.

ACR-7280 was prioritized from multiple series of CDK11 inhibitor compounds the company identified through its co-crystallography and AP3-driven discovery platform. AP3-based indication finding identified acute myeloid leukemia (AML) as a predicted sensitive tumor type, and ACR-7280 has shown complete tumor regression in in vivo AML xenograft models. Moreover, it has demonstrated potent preclinical anti-tumor activity across AML models, including NPM1-mutated and KMT2A-rearranged tumors, as well as strong synergy in combination with both venetoclax and menin inhibitors across several AML models. Based on this, initial development will focus on AML, both as single agent and in combination.

“ACR-7280 provides another powerful validation of our AP3 innovation engine,” said Peter Blume-Jensen, M.D., Ph.D., chief executive officer, president and co-founder of Acrivon. “AP3 profiling and analyses enabled us to identify ACR-7280 as a highly selective CDK11 inhibitor with optimized, desirable cellular pathway effects, which has translated to complete tumor regression in aggressive AML mouse models. While CDK11 has historically been a difficult target to drug, we believe ACR-7280 provides a first-in-class opportunity with broad potential in refractory/relapsed AML. The oral administration route may also provide flexibility for combining with standard-of-care agents, like venetoclax and menin inhibitors, potentially in earlier line settings. We look forward to advancing ACR-7280 swiftly towards the clinic, with IND submission on track for the first half of 2027.”

CDK11 is a challenging but compelling target with multiple isoforms and broad roles in cell cycle control, spanning transcription, pre-mRNA splicing and mitosis. ACR-7280 was rationally designed using the AP3 platform to achieve optimal on-target pathway effects, the same approach that was used to design ACR-2316, the company’s potential first-in-class, oral WEE1/PKMYT1 inhibitor which was rapidly advanced to the randomized dose expansion phase of its Phase 1/2 study.

About Acrivon Therapeutics
Acrivon is a clinical-stage biopharmaceutical company discovering and developing precision medicines utilizing its proprietary Generative Phosphoproteomics AP3 platform. The platform allows the company to interpret and quantify compound specific, drug-regulated pathway activity levels inside the intact cell in an unbiased manner, yielding terabytes of proprietary data and delivering rapid, actionable insights. The AP3 platform is comprised of a growing suite of powerful, internally-developed tools, including the AP3 Data Portal, converting multimodal data into structured data for generative AI analyses, the AP3 Kinase Substrate Relationship Predictor and the AP3 Interactome. These distinctive capabilities enable the company to go beyond the limitations of traditional drug discovery, as well as current AI-based target-centric drug discovery and rapidly design highly differentiated compounds with desirable pathway effects through intracellular protein network analyses and advance these agents into the clinic for streamlined development.

Acrivon is currently advancing its lead program, ACR-368 (also known as prexasertib), a selective small molecule inhibitor targeting CHK1 and CHK2 in a potentially registrational Phase 2 trial for endometrial cancer (EC). The company has received Fast Track designation from the Food and Drug Administration, or FDA, for the investigation of ACR-368 as a monotherapy based on OncoSignature-predicted sensitivity in patients with EC. The FDA has granted a Breakthrough Device designation for the ACR-368 OncoSignature assay for the identification of patients with endometrial cancer who may benefit from ACR-368 treatment.

Acrivon is also leveraging its proprietary Generative AI-driven Phosphoproteomics AP3 platform for developing its co-crystallography-driven, internally discovered pipeline programs. These include ACR-2316, a novel, potent, selective WEE1/PKMYT1 inhibitor designed for superior single-agent activity. The Phase 1/2 study of ACR-2316 is advancing in a randomized dose expansion phase. Initial data has shown a highly differentiated, favorable safety profile primarily limited to only transient, mechanism-based hematological adverse events, predominantly only neutropenia. Clinical activity has been observed across multiple tumor types, including small cell lung cancer (SCLC), squamous non-small cell lung cancer (NSCLC) and lung adenocarcinoma, tumor types not shown sensitive to current single-agent WEE1 or PKMYT1 inhibitors. Durable clinical activity has been observed, with certain lung cancer subjects remaining on treatment for more than one year.

In addition, the company is advancing ACR-7280, its next AP3-enabled, potential first-in-class program, an oral CDK11 inhibitor which is currently being advanced in IND-enabling studies. AP3 indication finding identified AML as a predicted sensitive tumor type, and in preclinical studies, ACR-7280 demonstrated potent anti-tumor activity and complete tumor regression in aggressive AML models.

Forward-Looking Statements
This press release includes certain disclosures that contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 about us and our industry that involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this press release, including statements regarding our future results of operations or financial condition, business strategy and plans and objectives of management for future operations, are forward-looking statements. In some cases, you can identify forward-looking statements because they contain words such as “anticipate,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” or “would” or the negative of these words or other similar terms or expressions. Forward-looking statements are based on Acrivon’s current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. Factors that could cause actual results to differ include, but are not limited to, risks and uncertainties that are described more fully in the section titled “Risk Factors” in our reports filed with the Securities and Exchange Commission. Forward-looking statements contained in this press release are made as of this date, and Acrivon undertakes no duty to update such information except as required under applicable law.

Acrivon intends to use its website as a means of disclosing material non-public information and for complying with its disclosure obligations under Regulation FD. For more information, please visit www.acrivon.com.

Investor and Media Contacts:
Adam D. Levy, Ph.D., M.B.A.
alevy@acrivon.com

Alexandra Santos
asantos@wheelhouselsa.com

Batch sufficient to supply the proposed Canadian Phase 3 trial, a clinical trial in Israel in partnership with MAPS and a commercial export to treat PTSD in Australia

Health Canada-authorized trial to evaluate efficacy and safety of two sessions of MDMA-assisted therapy in up to 100 veterans and frontline workers

VANCOUVER, British Columbia, Oct. 20, 2026 (GLOBE NEWSWIRE) —  Optimi Health Corp. (Nasdaq: OPTH, CSE: OPTI, FSE: 8BN) (“Optimi” or the “Company”), a commercial-stage pharmaceutical manufacturer of regulated psychedelic drug products, today announced the completion of its latest production batch of its MDMA (3,4-methylenedioxymethamphetamine) finished drug product. The capsules were manufactured at Optimi’s GMP facility in Princeton, British Columbia, under its Health Canada Drug Establishment Licence, and are expected to supply three programs: the recently announced proposed Phase 3 clinical trial of MDMA-assisted therapy in Canada (the “Proposed Phase 3 Trial”) for the treatment of post-traumatic stress disorder (“PTSD”), its next commercial export to Australia planned before the end of 2026, and a previously announced clinical trial in Israel in partnership with the Multidisciplinary Association for Psychedelic Studies (“MAPS”).

The Proposed Phase 3 Trial is intended to enroll up to 100 participants across multiple sites in Canada, focusing on veterans and current or former frontline workers. Participants are expected to receive the Company’s synthetic MDMA hydrochloride, supplied in two dosage formats, during two supervised sessions combining MDMA and psychotherapy spaced several weeks apart, with follow-up evaluations after the final session. The primary efficacy endpoint will be change in the Clinician-Administered PTSD Scale (CAPS-5), which is the standard clinician-rated instrument for assessing PTSD severity. The Proposed Phase 3 Trial is expected to begin in 2027.

Optimi has received Australian import permits for MDMA, with the next shipment planned before the end of 2026 to supply clinics and pharmacies across the country through Optimi Australia. In Australia, clinicians are authorized to prescribe MDMA capsules to patients with PTSD under the Therapeutic Goods Administration’s Authorised Prescriber Scheme, with reimbursement from public and private payers including the Department of Veterans’ Affairs, the National Disability Insurance Scheme, WorkCover, and Medibank. More than 750 clinicians have completed Mind Medicine Australia’s Certificate in Psychedelic-Assisted Therapies, and Optimi is not aware of any reported serious adverse events among patients since commercial supply began in 2024.

“Veterans in Australia can already access MDMA-assisted therapy through their own government. Veterans in Canada cannot,” said Dane Stevens, Optimi Chief Executive Officer and Co-Founder. “The Canadian Phase 3 trial is how we hope to close that gap, and the medicine for that trial is already made. We are proud to supply MDMA commercially to clinics in Australia, and we are keeping a keen eye on the United States and other jurisdictions as access expands.”

The safety and efficacy of MDMA-assisted therapy to treat PTSD is still under investigation in Canada, and none of Optimi’s MDMA drug products have received market authorization by Health Canada.

As previously announced on November 26, 2025, Optimi supplies the MDMA capsules for MAPS Israel’s Healing October 7^th project, which includes a clinical trial for PTSD that has received formal approval from the Israeli Ministry of Health. Further details on this clinical trial can be found in Optimi’s November 26, 2025 press release.

About Optimi Health Corp.

Optimi Health Corp. is a commercial-stage pharmaceutical company focused on manufacturing and distributing GMP-grade psychedelic drug products for mental health therapies. As a Health Canada-licensed pharmaceutical manufacturer, Optimi produces validated MDMA and botanical psilocybin drug products at its GMP-compliant facilities in British Columbia, Canada. Optimi supplies both active pharmaceutical ingredients and finished dosage forms to regulated clinical and therapeutic programs internationally, with products currently prescribed to patients in Australia under the country’s Authorised Prescriber Scheme and accessible in Canada through the Special Access Program.

For more information, please visit optimi.net.

Forward-Looking Statements

This press release contains forward-looking statements and forward-looking information within the meaning of applicable securities laws, including statements regarding the Proposed Phase 3 Trial, the anticipated enrolment of patients in such trial, the anticipated structure, timing, evaluation metrics and other key components of such trial, the utilization of the data derived from the trial, and the ability to conduct evaluations as part of the trial, the potential benefits of MDMA, the planned export of MDMA to Australia and Israel and the timing thereof, the anticipated use of this production batch, the Company’s ability to manufacture and ship products from its Canadian facility, and the Company’s positioning in the regulated psychedelic medicine market. Forward-looking statements and forward-looking information are often identified by words such as “expects,” “anticipates,” “believes,” “intends,” “plans,” “estimates,” “may,” “will,” “would,” “could,” or similar expressions. Forward-looking statements and forward-looking information are based on several assumptions and are subject to a number of known and unknown risks and uncertainties, many of which are beyond the Company’s control, which could cause actual results and events to differ materially from those that are disclosed in or implied by such forward-looking statements. Accordingly, there are or will be important factors that may cause actual results to differ from expected results. These factors include those described under “Risk Factors” in the Company’s registration statement on Form F-1, as amended, and other filings with the U.S. Securities and Exchange Commission made from time to time which are available at www.sec.gov and on SEDAR+ at www.sedarplus.ca and in the Company’s continuous disclosure filings available under its SEDAR+ profile at www.sedarplus.ca. These forward-looking statements reflect current expectations of management regarding future events and speak only as of the date of this press release. Except as expressly required by applicable law, the Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise. New factors emerge from time to time, and it is not possible for the Company to predict all of them or assess the impact of each factor or the extent to which any factor, or combination of factors, may cause results to differ materially from those contained in any forward-looking statement. Any forward-looking statements contained in this press release are expressly qualified in their entirety by this cautionary statement.

Neither the Canadian Securities Exchange nor the Canadian Investment Regulatory Organization accepts responsibility for the adequacy or accuracy of this release.

Company Contact:
Dane Stevens, CEO
(778) 761-4551
investors@optimi.net

Investor Relations Contact:
CORE IR
IR@Optimi.net

Australian Inquiries:
Adrian Jones, Commercial Lead, Optimi Australia
adrian@optimihealth.ca
www.optimi.com.au

Transaction to benefit patients through expanded access and support Myriad’s strategic priorities

SALT LAKE CITY and BURLINGTON, N.C., Oct. 20, 2026 (GLOBE NEWSWIRE) — Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, and Labcorp (NYSE: LH), a global leader in innovative and comprehensive laboratory services, today announce they have entered into a definitive agreement for Myriad to sell its Prenatal Health testing business, which includes the Prequel^®, Foresight^®, SneakPeek^®, and FirstGene^® tests, to Labcorp for $210 million in cash, plus the value of the inventory of the Prenatal Health testing business at closing.

“This announcement is the direct outcome of our disciplined strategic review process, which is focused on sharpening our portfolio, enhancing operational execution and driving shareholder value,” said Sam Raha, President and CEO, Myriad Genetics. “This transaction is expected to be accretive to Myriad’s revenue growth and profitability, while meaningfully strengthening the balance sheet to support continued investment in our strategic priorities tied to the cancer care continuum and long-term value creation. Working closely with Labcorp, one of the nation’s largest laboratory service providers, we expect a smooth transition that preserves uninterrupted patient access to our prenatal tests.”

When complete, the transaction is expected to provide more patients and physicians with expanded access to Labcorp’s comprehensive, high-quality laboratory services, convenient patient service center network, robust data analytics and digital tools.

“This transaction supports Labcorp’s specialty testing growth strategy,” said Bryan Vaughn, Executive Vice President and President of Diagnostics, Labcorp. “Myriad Genetics has built a highly complementary reproductive genetics platform, supported by innovative screening solutions and deep scientific expertise. By combining these capabilities with Labcorp’s operational strength and high-quality women’s health portfolio, we aim to improve outcomes, expand access to advanced screening solutions and enhance the patient and provider experience.”

Labcorp expects the transaction to add approximately $160 million in revenue in year one, to be slightly accretive to adjusted earnings in year one, and to reach average diagnostics segment margins by end of year two, once fully integrated.

Over the last twelve months, Myriad’s Prenatal Health testing portfolio has been used by thousands of providers and over 600,000 patients. Myriad plans to provide further commentary regarding this transaction, and other related organizational changes, on its third quarter earnings call on November 4, 2026.

The deal is subject to regulatory clearance and customary closing conditions, and the transaction is expected to close by early 2027.

Guggenheim Securities, LLC is acting as exclusive financial advisor, and Covington & Burlington LLP is acting as legal advisor to Myriad Genetics.

Barclays is acting as financial advisor, and Polsinelli is acting as legal advisor to Labcorp.

About Myriad Genetics 
Myriad Genetics is a leading molecular diagnostic and precision medicine company committed to advancing health and well-being for all. Myriad Genetics develops and commercializes molecular tests that help patients and providers uncover genetic insights. Our tests assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where molecular insights can significantly improve patient care, support earlier detection, enable more precise treatment and contribute to lowering healthcare costs. For more information, visit myriad.com.

About Labcorp

Labcorp (NYSE: LH) is a global leader of innovative and comprehensive laboratory services that helps doctors, hospitals, pharmaceutical companies, researchers and patients make clear and confident decisions. We provide insights and advance science to improve health and improve lives through our unparalleled diagnostics and drug development laboratory capabilities. The company’s nearly 71,000 employees serve clients in approximately 100 countries, provided support for more than 85% of the new drugs and therapeutic products approved by the FDA in 2025 and performed more than 750 million tests for patients around the world. Learn more at www.labcorp.com.

Myriad Genetics Safe Harbor Statement

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the sale of Myriad’s Prenatal Health testing business; the expected benefits of the transaction, including that it will be accretive to Myriad’s revenue growth and profitability, strengthen its balance sheet, and support investment in its strategic priorities; and the expectation that the transaction will close by early 2027. These “forward-looking statements” are management’s expectations of future events as of the date hereof and are subject to known and unknown risks and uncertainties that could cause actual results, conditions, and events to differ materially and adversely from those anticipated. Such factors include those risks described in the Myriad’s filings with the U.S. Securities and Exchange Commission, including Myriad’s Annual Report on Form 10-K filed on February 24, 2026, as well as any updates to those risk factors filed from time to time in Myriad’s Quarterly Reports on Form 10-Q or Current Reports on Form 8-K. Myriad is not under any obligation, and it expressly disclaims any obligation, to update or alter any forward-looking statements, whether as a result of new information, future events or otherwise except as required by law.

Labcorp Cautionary Statement Regarding Forward-Looking Statements

This press release contains forward-looking statements, including, but not limited to, statements with respect to the anticipated benefits of the transaction for providers and patients, its advancement of Labcorp’s strategic priorities, and the expected financial impact of the transaction, including expected post-closing revenues and margins, and the timing of achieving such financial results.

Each of the forward-looking statements is subject to change based on various important factors, many of which are beyond Labcorp’s control. These factors, in some cases, have affected and in the future (together with other factors) could affect Labcorp’s ability to implement its business strategy, and actual results could differ materially from those suggested by these forward-looking statements. As a result, readers are cautioned not to place undue reliance on any of the forward-looking statements. 

Labcorp has no obligation to provide any updates to these forward-looking statements even if its expectations change. All forward-looking statements are expressly qualified in their entirety by this cautionary statement. Further information on potential factors, risks and uncertainties that could affect operating and financial results is included in Labcorp’s most recent Annual Report on Form 10-K under the heading RISK FACTORS and in subsequent quarterly reports on Form 10-Q and its other filings with the SEC. The information in this press release should be read in conjunction with a review of Labcorp’s filings with the SEC including the information in its most recent Annual Report on Form 10-K under the heading “MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS”. 

Myriad Contacts:
Investors:	Matt Scalo (801) 584-3532 IR@myriad.com
Media:	Andria Rosell (385) 202-3510 PR@myriad.com
Labcorp Contacts:
Investors:	Nickolo Russo Investor@Labcorp.com
Media:	Racquel White Media@Labcorp.com

Split-adjusted trading began Oct. 20, 2026, under the temporary symbol NGTFD

LOS ANGELES, Oct. 20, 2026 (GLOBE NEWSWIRE) — via IBN — Nightfood Holdings, Inc. (OTC Pink: NGTFD) (“Nightfood” or the “Company”), doing business as TechForce Robotics, today announced that, effective at 12:01 a.m. Eastern Time on Oct. 20, 2026 (the “Effective Time”), the Company effected a 1-for-150 reverse stock split (the “Reverse Stock Split”) of all issued and outstanding shares of its common stock, par value $0.001 per share (the “Common Stock”).

As a result of the Reverse Stock Split, every 150 shares of issued and outstanding Common Stock were automatically combined into one share of Common Stock. The Reverse Stock Split applied proportionately to all holders of Common Stock and did not change any holder’s percentage ownership interest in the Company, except for immaterial changes resulting from the treatment of fractional shares. No fractional shares were issued. A holder who otherwise would have been entitled to receive a fractional share was rounded up to the next whole share.

The Reverse Stock Split reduced the number of issued and outstanding shares of Common Stock from approximately 543,899,213 immediately before the Effective Time to approximately 3,625,995 immediately after the Effective Time. The number of authorized shares of Common Stock did not change as a result of the Reverse Stock Split.

The Common Stock began trading on a split-adjusted basis on the OTC Pink market at market open on Oct. 20, 2026. For 20 trading days following the Effective Time, the Common Stock will trade under the temporary symbol NGTFD, after which its trading symbol will change to NGTF. Following the Reverse Stock Split, the CUSIP number for the Common Stock is 65412F200.

The Company’s transfer agent, ClearTrust, LLC, acted as the exchange agent for the Reverse Stock Split. Stockholders who held their shares in brokerage accounts or in “street name” were not required to take any action to effect the Reverse Stock Split.

The Reverse Stock Split is intended to increase the per-share trading price of the Common Stock and support the Company’s efforts to satisfy the applicable initial listing requirements of the Nasdaq Capital Market.

“The effectiveness of the Reverse Stock Split represents another important step in our Nasdaq uplisting process,” said Jimmy Chan, Chief Executive Officer of Nightfood Holdings. “Our team has worked diligently over the past 18 months to build the Company and position it for its next stage of growth. If achieved, a Nasdaq listing could enhance our market visibility, broaden access to institutional and retail investors, and create additional opportunities to advance strategic relationships and partnerships. While the proposed uplisting remains subject to Nasdaq’s approval and our satisfaction of all applicable listing requirements, we are proud to have reached this important milestone and remain focused on growing our AI-enabled robotics and semiconductor automation businesses.”

The Company has submitted an application to list its Common Stock on the Nasdaq Capital Market and continues to advance through Nasdaq’s review process. In connection with the application, the Company is working to demonstrate compliance with all relevant initial listing standards, including, as applicable, requirements relating to minimum bid price, market value of unrestricted publicly held shares, public float, trading liquidity, stockholder distribution and corporate governance. The Reverse Stock Split is intended to support the Company’s efforts to satisfy certain of these requirements; however, the Reverse Stock Split alone does not ensure that the Company will qualify for listing. Completion and timing of the proposed uplisting remain subject to Nasdaq’s continued review, the Company’s satisfaction of all applicable listing requirements and Nasdaq’s final approval. There can be no assurance that the Company will satisfy those requirements within any particular timeframe, that Nasdaq will approve the listing application, or that the proposed uplisting will be completed.

About Nightfood Holdings, Inc. (d/b/a TechForce Robotics)
Nightfood Holdings, Inc., doing business as TechForce Robotics, is an advanced robotics and automation company focused on delivering intelligent, scalable solutions for industrial and commercial applications. The Company integrates robotics, artificial intelligence and software-driven systems to optimize operations, improve efficiency and enable next-generation automation.

TechForce Robotics partners with organizations to design and deploy customized robotic solutions that address evolving operational requirements.

Learn more: www.techforcerobotics.com

About TechForce Advanced Manufacturing
TechForce Advanced Manufacturing, Inc. is a Nevada corporation formed to develop, manufacture, commercialize, install and support semiconductor automation and inspection systems. Its initial focus is expanding Wafer Sorter and AOI production for wafer-based semiconductor and CoWoS-related advanced-packaging applications, while pursuing future applications supporting emerging Chip-on-Panel-on-Substrate (“CoPoS”) manufacturing processes.

Forward-Looking Statements
Matters discussed in this press release contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “anticipate,” “believe,” “estimate,” “may,” “intend,” “expect,” “plan,” “project,” “target,” “will” and similar expressions identify forward-looking statements.

Forward-looking statements are based on management’s current expectations and assumptions. They are subject to risks, uncertainties, and other factors, many of which are beyond the Company’s control, that could cause actual results to differ materially from those expressed or implied. These risks and uncertainties include, among others:

• The Reverse Stock Split may not achieve its intended results, including increasing the market price of the Company’s Common Stock on a sustained basis;
• The market price of the Common Stock may decline after the Reverse Stock Split, and the Company’s market capitalization may fall;
• The Reverse Stock Split may reduce the liquidity of the Common Stock and increase the number of stockholders holding odd lots;
• Market reaction to the Reverse Stock Split may be negative;
• The Company may need to raise additional capital, and any such capital may not be available on acceptable terms, or at all; and
• Other risks described under “Risk Factors” in the Company’s Annual Report on Form 10-K for the fiscal year ended June 30, 2026, its subsequent Quarterly Reports on Form 10-Q, and its other filings with the Securities and Exchange Commission, available at www.sec.gov.

Readers should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Except as required by applicable law, the Company undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise.

Investor Relations, Media Relations and Corporate Communications
Investor Relations
ir@nightfoodholdings.com

Media Relations
media@nightfoodholdings.com

Corporate Communications:
IBN.Ai
Austin, Texas
www.IBN.Ai
512.354.7000 Office
Editor@IBN.Ai

H1 2026 Financial & Business Highlights

• Revenue was S$20.8 million, an increase of 221% compared to H1 2025.
• Net Income reached S$1.7 million, a strong turnaround from the net loss of S$0.8 million compared to H1 2025.
• Gross Profit amounted to S$7.5 million, an increase of 363% compared to H1 2025.
• Adjusted EBITDA reached S$3.0 million, a strong turnaround from the EBITDA deficit of S$0.1 million compared to H1 2025.
• The growth in revenue for H1 2026 is mainly due to the increase in revenue from the sale of precision cleaning systems which recorded a triple-digit growth compared to H1 2025.
• The H1 2026 results reflect JE Cleantech’s continued efforts since the last financial year to retain its solid customer base for precision cleaning systems while expanding its customer reach through strategic initiatives.

SINGAPORE, Oct. 20, 2026 (GLOBE NEWSWIRE) — Singapore-headquartered, NASDAQ-listed precision cleaning and cleantech equipment manufacturer JE Cleantech Holdings Ltd (NASDAQ: JCSE) (“JCSE” or “JE Cleantech” or the “Company” and, together with its subsidiaries, the “Group”) today announced encouraging financial results for the six-month period ended June 30, 2026 (“H1 2026”). The Company experienced growth in revenue and net income compared to the corresponding six-month period ended June 30, 2025 (“H1 2025”), with revenue of S$20.8 million, net income of S$1.7 million and adjusted EBITDA of S$3.0 million.

In H1 2026, JCSE’s revenue increased by 221% to S$20.8 million from S$6.5 million in the same corresponding period last year. The growth was driven by a 492% increase in sales of cleaning systems and other equipment and a 13% increase in our provision of centralized dishwashing and ancillary services business. JCSE also recorded a net income of S$1.7 million in H1 2026, compared to a net loss of S$0.8 million in the same corresponding period last year, indicating a significant turnaround for its business performance. The Company attributes its revenue and profit growth to its solid customer base for precision cleaning systems and its strategic efforts to expand that customer base.

The Group yielded gross profit and gross profit margin of S$7.5 million and 36.2% respectively, driven mainly by higher sales of precision cleaning systems at improved margins. This compares with S$1.6 million and 25.1% in H1 2025. Earnings per share was approximately S$0.32, compared to the basic losses per share of S$0.15 during the same period in 2025.

Commenting on JE Cleantech’s performance, Founder, Chairman and CEO Ms. Hong Bee Yin said, “We are pleased with JE Cleantech’s growth in H1 2026, and we remain committed to our pursuit of excellence, innovation, and sustainable growth. By adapting to market changes, enhancing customer relationships, and leveraging the longstanding relationships we have with our customers to build traction for our products and services, as well as closely monitoring our cost dynamics, we aim to continue our trajectory of success.”

– END –

About JE Cleantech Holdings Limited

JE Cleantech Holdings Limited is based in Singapore and is principally engaged in (i) the sale of precision cleaning systems and other equipment; and (ii) the provision of centralized dishwashing and ancillary services. Through its subsidiary, JCS-Echigo Pte Ltd, the Company designs, develops, manufactures, and sells cleaning systems for various industrial end-use applications primarily to customers in Singapore and Malaysia. Its cleaning systems are mainly designed for precision cleaning, with features such as particle filtration, ultrasonic or megasonic rinses with a wide range of frequencies, high pressure drying technology, high flow rate spray, and deionized water rinses, which are designed for effective removal of contaminants and to minimize particle generation and entrapment. The Company also provides centralized dishwashing services through its subsidiary, Hygieia Warewashing Pte Ltd, since 2013 and general cleaning services since 2015, both mainly for food and beverage establishments in Singapore. The Company has been listed on NASDAQ since 2022. For more information about JE Cleantech, please visit: www.jecleantech.sg.

Disclaimer: Forward-Looking Statements

This news release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements may be identified by such words or phrases as “should,” “intends,” “is subject to,” “expects,” “will,” “continue,” “anticipate,” “estimated,” “projected,” “may,” “I or we believe,” “future prospects,” “our strategy,” “aim” or similar expressions. Forward-looking statements made in this press release that relate to our future contract revenues among other things involve known and unknown risks and uncertainties that may cause the actual results to differ materially from those expected and stated in this announcement. We undertake no obligation to update “forward-looking” statements.

For media enquiries, please contact:        
Jason Long
Email address: enquiry@jecleantech.sg
Phone number: +65 63684198
Other number: +65 66029468

MANITOWOC, Wis., Oct. 20, 2026 (GLOBE NEWSWIRE) — Orion Energy Systems, Inc. (NASDAQ: OESX) (Orion Lighting), a provider of energy-efficient LED lighting, electric vehicle (EV) charging stations and maintenance services solutions, today announced that it has secured LED lighting, Electrical Infrastructure and EV charging station engagements from one of the world’s largest automobile manufacturers.

Orion noted that the combined work for this global automotive leader includes a suite of Orion capabilities including LED lighting and EV charging stations. These latest contracts exemplify the evolution of Orion’s long-term partnership with this automotive leader to provide an expanding portfolio of services, including Orion’s first EV deployment with this customer.

Orion’s new engagements with this longtime customer, which include several additional projects slated for later in the current fiscal year, entail deployments and upgrades of LED Lighting, Electrical Contracting and Infrastructure, and EV Charging Stations at U.S. manufacturing and distribution facilities operated by the automaker.

The work is part of an ongoing updating of the LED lighting and electrical infrastructure of manufacturing and distribution facilities operated by the customer. The projects represent revenue of up to $1.4 million in additional business for Orion in FY 2027.

“We are proud to be a trusted provider of LED lighting, Electrical infrastructure and EV Charging Stations to some of the most prominent and respected automakers on earth,” said Orion Chief Executive Officer Sally Washlow. “As these worldwide automotive industry leaders continue to enact broad-based upgrades of their facilities, they continually turn to Orion, the provider on whom they’ve depended for decades.”

About Orion Energy Systems (at www.orionlighting.com)
Orion provides energy efficient LED lighting and controls, electrical vehicle (EV) charging solutions, and electrical maintenance services. Orion specializes in turnkey design-through-installation solutions for large national customers as well as projects through ESCO and distribution partners. Orion is committed to helping customers achieve their business, financial and environmental goals with high quality, innovative and safe solutions delivered with high levels of customer service and reliability.

Engage with Us
X: @OrionLighting and @OrionLightingIR
StockTwits: @OESX_IR

Investor Relations Contacts
Per Brodin, CFO	Robert Ferri
Orion Energy Systems, Inc.	Robert Ferri Partners
pbrodin@oesx.com	(415) 575-1589 robert.ferri@robertferri.com

AVSAM proposal targets intelligent, bidirectional lunar power distribution; Lunar Utilities Corporation seeks to develop commercial power and robotic charging services

Illustrative schematic of proposed Lunar Utilities Corporation power network, including elevated solar arrays, power distribution, communications and robotic charging.

AUSTIN, Texas, Oct. 20, 2026 (GLOBE NEWSWIRE) — Astrotech Corporation (NASDAQ: ASTC) today announced it has submitted a proposal, developed in collaboration with Skycorp Incorporated, to NASA for the NASA Next Space Technologies for Exploration Partnerships-3 (NextSTEP-3) Lunar Enabling Infrastructure Accelerator (LEIA), Appendix A, Topic 1: Vertical Solar Array. The proposed project, Astrotech Vertical Solar Array Maturation (AVSAM), would advance critical elements of the Astrotech Mobile Power System (AMPS) for potential future lunar surface use.

The proposal targets maturation from Technology Readiness Level (TRL) 4 to TRL 6 through design, prototype integration and environmental testing. The proposed system is currently designed around a 120-volt direct-current interface, with 6 kilowatts of continuous power transfer over a 100-meter connection, bidirectional power flow, and a 10-kilowatt short-duration startup surge.

If successfully developed, AMPS is expected to combine power system controllers, power management and distribution hardware, low-temperature cabling and connectors, and thermal protection suited to the lunar polar environment. The architecture proposes local telemetry, fault isolation and intelligent management of multiple power sources and users, supporting interoperability among lunar equipment.

If the proposal is selected by NASA, Astrotech and Skycorp propose an accelerated development and demonstration effort, expected to culminate in an integrated system test at Astrotech facilities in Austin, Texas. Should the proposal be selected, Skycorp will lead systems engineering and technical development and Astrotech will provide infrastructure, facilities, procurement and program financial management.

Astrotech also plans to evaluate and potentially develop Lunar Utilities Corporation (LUC) as a commercial lunar utility offering power services to NASA and private customers. The broader vision includes elevated solar arrays, energy storage, electrical distribution and charging services for lunar robots and mobility equipment, with power purchase agreements and other commercial service arrangements.

“Our objective is to help establish the electric utility infrastructure that will make sustained lunar activity possible,” said Thomas B. Pickens III, Chairman and Chief Executive Officer of Astrotech. “We see the opportunity to apply terrestrial utility operating principles to a scalable lunar power network that can serve multiple customers.”

Skycorp brings experience developing and demonstrating space power, communications and flight hardware systems, including work at NASA Desert RATS and on lunar and International Space Station missions.

The AVSAM proposal is a submission for consideration under a NASA solicitation. It is not a NASA award or a commitment of NASA funding. The conceptual lunar outpost illustration accompanying this release depicts potential future commercial applications and is not a representation of current development or the specific hardware deliverables under the proposed NASA effort.

About Astrotech Corporation
Astrotech Corporation (NASDAQ: ASTC) is a science and technology company headquartered in Austin, Texas. The Company creates, operates and scales innovative businesses through its subsidiaries and technology platforms, including space-related technology, advanced instrumentation, mass spectrometry, gas chromatography, process-control and environmental analysis technologies. For more information, visit www.astrotechcorp.com

Forward-Looking Statements
This press release contains “forward-looking statements” that are made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements are subject to risks, trends, and uncertainties that could cause actual results to be materially different from the forward-looking statement. These statements may be identified by terms such as “aims,” “anticipates,” “believes,” “contemplates,” “continue,” “could,” “estimates,” “expect,” “forecast,” “guidance,” “intends,” “may,” “plans,” “possible,” “potential,” “predicts,” “preliminary,” “projects,” “seeks,” “should,” “targets,” “will” or “would,” or the negatives of these terms, variations of these terms or other similar expressions. These forward-looking statements include, but are not limited to, statements regarding the AVSAM proposal and its submission, evaluation, selection or award under NASA’s NextSTEP-3; the proposed system’s design parameters; the proposed development and demonstration schedule and the planned integrated system test at Astrotech’s facilities; the Company’s teaming arrangement with Skycorp; the allocation of systems engineering, technical development, infrastructure, facilities, procurement and program financial management responsibilities; the development of a commercial lunar utility and related power, energy-storage, distribution and robotic charging services for NASA and private customers, including potential power purchase agreements and other commercial service arrangements; and the timing, cost, capacity, reliability, qualification, deployment, operation or commercialization of lunar power infrastructure,

Forward-looking statements are based on current expectations, estimates, forecasts, and projections, as well as management’s current beliefs and assumptions, and are subject to risks, uncertainties, and other factors that could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include, among others, the early-stage nature of the program; the possibility that the proposal is not submitted, is not accepted, is not selected or does not result in an award, and that NASA’s solicitation is amended, delayed or not finalized; the Company’s dependence on Skycorp Incorporated and other third parties for systems engineering and technical development; the risk that the proposed technologies do not achieve target performance, reliability or environmental qualification in the lunar polar environment; schedule risk associated with the proposed accelerated development and demonstration effort; battery, cabling, connector and thermal performance and degradation; the availability and cost of lunar transportation and launch services, and launch, landing, deployment and maintenance risks; the absence of any binding power purchase agreement, customer commitment, partner agreement, financing commitment or launch contract; the Company’s ability to secure strategic partners, customers, government support or financing; delays in or failure to obtain applicable governmental authorizations, including launch, payload, communications and export-control authorizations; competition; supply-chain constraints; the uncertain timing and development of commercial lunar markets; the adverse impact of inflationary pressures, global economic conditions and geopolitical events; and whether the market will accept the Company’s products and services, as well as other risk factors and business considerations described in the Company’s Securities and Exchange Commission filings, including the Company’s most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q.

Any forward-looking statements in this document should be evaluated in light of these important risk factors. The AVSAM proposal is a submission for consideration under a NASA solicitation and does not constitute a NASA selection, award, contract, authorization, endorsement or funding commitment. The contemplated lunar energy-storage application remains in the evaluation and development stage. While we do not intend to directly harvest, manufacture, distribute or sell cannabis or cannabis products, we may be detrimentally affected by a change in enforcement by federal or state governments and we may be subject to additional risks in connection with the evolving regulatory area and associated uncertainties. Any such effects may give rise to risks and uncertainties that are currently unknown or amplify others mentioned herein. Although the Company believes the expectations reflected in its forward-looking statements are reasonable and are based on reasonable assumptions, no assurance can be given that these assumptions are accurate or that any of these expectations will be achieved (in full or at all) or will prove to have been correct. Moreover, such statements are subject to a number of assumptions, risks and uncertainties, many of which are beyond the control of the Company, which may cause actual results to differ materially from those implied or expressed by the forward-looking statements. In addition, any forward- looking statements included in this press release represent the Company’s views only as of the date of its publication and should not be relied upon as representing its views as of any subsequent date. The Company assumes no obligation to correct or update these forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.

Company Contact
Scott Bartley
Interim Chief Financial Officer
Astrotech Corporation
(512) 485-9530

Coralboard SL reaches general availability and ships now from DigiKey. New Coralboard SR joins the portfolio. Torq™ Edge AI compiler now also available for Coralboard.

SAN JOSE, Calif., Oct. 20, 2026 (GLOBE NEWSWIRE) — Synaptics^® Incorporated (Nasdaq: SYNA) today announced that the latest version of the Synaptics Coralboard is available for purchase through DigiKey starting today. Developed in collaboration with Google Research, the Coralboard SL is powered by the Synaptics Astra^® SL2619, which integrates the 1 TOPS Synaptics Torq™ NPU featuring the first implementation of the Coral NPU. Following an initial limited-edition run, this version moves the platform to general availability through DigiKey’s global distribution network. The Coralboard portfolio is built for ultra-low power, always-on applications using ambient sensing, and is designed to deliver efficient, accelerated on-device inference for resource-constrained form factors.

Expanding the ecosystem and broadening developer choice, Synaptics also introduced the Coralboard SR, based on the newly launched Synaptics Astra® SR200 Series of xMCUs, a new class of AI-native, multimodal processors combining heterogeneous compute with integrated, high-bandwidth memory to bring vision, voice, and graphics to Edge and Physical AI systems.

The Coralboard family is designed to deliver a consistent Edge AI developer experience across the SL and SR versions thanks to the MLIR-based Synaptics Torq™ compiler and runtime. Synaptics’ Torq open-source toolchain supports widely used ML frameworks, giving developers a single path from model optimization through deployment. With an open, collaborative development and continuous refinement approach, Torq is designed to deliver day-0 support for Edge AI model families, such as Google Gemma3 270M (achieves up to 12-16 tokens/second with INT8 and 4-bit quantization respectively), LiquidAI LFM2.5, and Ultralytics YOLO26, employing active-research techniques such as batch-prefill and dynamic quantization.

Torq enables optimal execution across the Synaptics Astra processor portfolio by natively mapping model network layers to accelerator engines. Additionally, the open-source nature of Torq allows users to deploy agentic AI tools and workflows that parse through the source code and assist in feature-addition, performance customization, and debugging, promoting true Edge AI developer freedom.

The Synaptics Coralboard brings together the open hardware and software foundation for private, efficient Edge AI applications across wearables, hearables, smart home appliances, automation hubs, industrial control systems, and robotics.

Synaptics Coralboard SL comes with:

• Astra SL2619 with 2x 2GHz Arm^® Cortex^® A55, Cortex-M52, 1 TOPS Torq/Coral NPU
• 2GB DDR4, MicroSD card slot, NOR flash memory
• Camera and display support via CSI/DSI and USB
• QWICC and mikroBUS connectors
• Add-on HATs for HDMI display, power, camera, and digital mics
• Wi-Fi^®/Bluetooth^® connectivity through an M.2 expansion slot

Synaptics Coralboard SR offers:

• Astra SR250 Series with 800MHz Arm Cortex M85, Cortex M52, 400 GOPS Torq/Coral NPU
• Integrated SRAM up to 8MB and high-bandwidth custom DRAM up to 256MB
• MicroSD card slot, NOR flash memory
• Multi-camera and display support via CSI/DSI and USB, dual ISPs, digital mics
• QWICC and mikroBUS connectors
• Wi-Fi/Bluetooth connectivity

Building on its work with Google Research, Synaptics extends the Coralboard portfolio with a shared goal to defragment the developer experience for Edge AI.

“Our collaboration with Synaptics started from a shared view of what open Edge AI hardware should look like, and the Coralboard SL was the first developer-ready solution we co-created,” said Billy Rutledge, Director, Google Research. “The Synaptics Astra SR200 series now brings the second generation of the Coral NPU IP with RISC-V vector core support into silicon, and the Coralboard SR puts that in developers’ hands. Each version widens what can run at the Edge without asking developers to start over.”

“The Synaptics Coralboard is a starting line the whole ecosystem can share,” said Olivier Lacombe, Product Director, Google DeepMind. “With Gemma models optimized and ready to run on Coralboard, developers can stop solving the same integration puzzle, scale the model as their application requirements evolve, and start building the things only they can imagine.”

“The Synaptics Coralboard was designed to address a developer need for an open, cost-optimized AI-native Edge platform for the IoT,” said Vikram Gupta, SVP & GM, Edge Compute and Connectivity Division, Synaptics. “The limited-edition run validated this thinking, and our partnership with DigiKey now puts the Coralboard within reach of engineers worldwide. Integrating the open-source Synaptics Torq™ compiler, AI/ML developers get a unified, consistent experience that scales across our Astra portfolio.”

“Edge AI is where the next wave of design activity is happening, and developers need a starting point they can trust,” said Mike Slater, Vice President of Global Business Development, DigiKey. “As the exclusive distribution partner for the Synaptics Coralboard, we are putting an open, production-ready design platform in front of millions of engineers in our global network.”

“We’re excited to see Liquid.AI’s LFM2.5 Edge AI models running on the Synaptics Astra^® SL2619. Our models are going to help drive new opportunities for Edge AI,” said Alan Wong, Head of Silicon Partnerships at Liquid AI.

“NPU compilers have largely been closed, black-box toolchains, which makes an open-source compiler like Synaptics Torq™ stand out in our industry,” said Daniel Chang, CEO, ENERZAi. “As a contributor to the Torq project, we’ve seen first-hand how its open, MLIR-based design gives developers the freedom to inspect, extend, and optimize models to accelerators. At the same time, as an Edge AI software company commercializing 1.58-bit on-device AI agents, we see Torq as a flexible and compelling path to bring these models into real-world products.”

Availability
The Synaptics Coralboard is available to order from DigiKey starting October 20, 2026. For product details, documentation, and to get started, visit https://developer.synaptics.com/docs/developer-kits/coralboard.

About Synaptics Incorporated
Synaptics (Nasdaq: SYNA) is driving innovation in AI at the Edge, bringing AI closer to end users and transforming how we engage with intelligent connected devices, whether at home, at work, or on the move. As a go-to partner for forward-thinking product innovators, Synaptics powers the future with its cutting-edge Synaptics Astra^® AI-Native embedded compute, wireless connectivity, and multimodal sensing solutions. We’re making the digital experience smarter, faster, more intuitive, secure, and seamless. From touch, display, and biometrics to AI-driven wireless connectivity, video, vision, audio, speech, and security processing, Synaptics is the force behind the next generation of technology enhancing how we live, work, and play. Follow Synaptics on LinkedIn, Facebook, Instagram, and YouTube, or visit www.synaptics.com.

Forward-Looking Statements Safe Harbor
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the capabilities and performance of the Synaptics Coralboard and Astra processors, the Torq compiler toolchain, developer adoption of the platform, the planned roadmap with multiple board versions at different performance and power points, and market opportunities in edge AI and physical AI applications. These statements involve risks and uncertainties including product development and availability delays, competitive pressures in edge AI hardware and software, actual developer adoption rates, supply chain constraints for semiconductors and components, the ability to deliver stated performance specifications, the sustainability of open-source projects, and macroeconomic conditions affecting demand. Actual results could differ materially from those projected. For more information on risks, please refer to Synaptics’ most recent Form 10-K and 10-Q filings with the SEC. Synaptics disclaims any obligation to update forward-looking statements except as required by law.

Synaptics and the Synaptics logo are trademarks of Synaptics in the United States and/or other countries. All other marks are the property of their respective owners.

Media Contact
Neeta Shenoy
Synaptics
+1-408-425-2654
neeta.shenoy@synaptics.com

LONDON, Oct. 20, 2026 (GLOBE NEWSWIRE) — Navigator Holdings Ltd. (described herein as “Navigator Gas” or the “Company”) (NYSE: NVGS), the owner and operator of the world’s largest fleet of handysize liquefied gas carriers, announces today that it will release its results for the three months ended September 30, 2026, after markets close in New York, on Tuesday, November 3, 2026.

The next day, Wednesday, November 4, 2026, at 10:00 A.M. E.S.T., the Company’s management team will host a Zoom conference call and slide presentation to discuss the financial results.

Zoom Conference Call Details
Participants should register for the conference call and slide presentation through the following link:

https://us06web.zoom.us/webinar/register/WN_Xvtd0olWQCq4ZZhQvcuFww

Or join by phone:
United States:	+1 929 436 2866
United Kingdom:	+44 330 088 5830

For a full list of US and international numbers available, please click on the link below:

International Dial-in numbers

Webinar ID: 845 4443 1040
Passcode: 268017

The conference call and slide presentation will be available for replay on Navigator Gas’ website (www.navigatorgas.com) under Latest Quarter Results in the Investors Centre section.

About Navigator Gas
Navigator Holdings Ltd. (described herein as “Navigator Gas” or the “Company”) is the owner and operator of the world’s largest fleet of handysize liquefied gas carriers and a global leader in the seaborne transportation services of petrochemical gases, such as ethylene and ethane, liquefied petroleum gas (“LPG”) and ammonia and owns a 50% share, through a joint venture, in an ethylene export marine terminal at Morgan’s Point, Texas on the Houston Ship Channel, USA. Navigator Gas’ fleet currently consists of 48 semi- or fully-refrigerated liquefied gas carriers, 19 of which are ethylene and ethane capable. The Company plays a vital role in the liquefied gas supply chain for energy companies, industrial consumers and commodity traders, with its sophisticated vessels providing an efficient and reliable ‘floating pipeline’ between the parties, connecting the world today, creating a sustainable tomorrow.

Navigator Gas’ common stock trades on the New York Stock Exchange under the symbol “NVGS”.

For further information or media enquiries, please contact:

Navigator Gas Investor Relations
Email: investorrelations@navigatorgas.com

Randy Giveans
Chief Investor Relations Officer and EVP of Business Development
Email: randy.giveans@navigatorgas.com
1200 Smith Street, Suite 1000, Houston, Texas, U.S.A. 77002
Tel: +1-713-373-6197

Alexander Walster
Media Contact
Email: communications@navigatorgas.com   
Verde, 10 Bressenden Place, London, SW1E 5DH, UK
Tel: +44 (0)7857 796 052, +44 (0)20 7045 4114

Investor Relations / Media Advisors
Nicolas Bornozis / Paul Lampoutis
Capital Link – New York
Tel: +1-212-661-7566
Email: navigatorgas@capitallink.com   

Forward looking statements

This press release contains certain “forward-looking” statements (as defined by the Securities and Exchange Commission) concerning plans and objectives of management for future operations or economic performance, or assumptions related thereto. In addition, we and our representatives may from time to time make other oral or written statements that are also forward-looking statements. In some cases, you can identify the forward-looking statements by the use of words such as “may,” “could,” “should,” “will,” “would,” “expect,” “plan,” “anticipate,” “intend,” “forecast,” “believe,” “estimate,” “predict,” “propose,” “potential,” “continue,” “scheduled,” or the negative of these terms or other comparable terminology.

These forward-looking statements involve many risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include but are not limited to those set forth in the periodic reports Navigator files with the U.S. Securities and Exchange Commission.

All forward-looking statements included in this press release are made only as of the date of this press release. New factors emerge from time to time, and it is not possible for us to predict all of these factors. Further, we cannot assess the impact of each such factor on our business or the extent to which any factor, or combination of factors, may cause actual results to be materially different from those contained in any forward-looking statement. We expressly disclaim any obligation to update or revise any forward-looking statements, whether because of future events, new information, a change in our views or expectations, or otherwise. We make no prediction or statement about the performance of our common stock.

Category: Financial